Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

By W. Sandborn, C. Su, Bruce E. Sands, G. D'Haens, Severine Vermeire, Stefan Schreiber, S. Danese, B. Feagan, W. Reinisch, W. Nieżychowski and 8 more. New England Journal of Medicine, 2017

877 citations recorded by the source corpus.

Subfields: Complementary and alternative medicine, Genetics, Rheumatology

View Paper: https://www.semanticscholar.org/paper/3a792449ee191ca507bb92087ac6d510bb798bff

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Ashwin N. Ananthakrishnan

Citations in the corpus

• ACG Clinical Guideline: Ulcerative Colitis in Adults (2019, background): “The rates of serious adverse events were comparable across the 3 groups, with the exception of a higher rate of herpes zoster infection in the tofacitinib group (139).”